Ratings by BMO Capital (David Lebowitz)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 8/18/2026 | Aktis Oncology | AKTS | New Coverage | Outperform (N/A) |
24.72 (24.07) |
-2.63% | Details | |
| 8/18/2026 | Bicara Therapeutics Inc | BCAX | New Coverage | Outperform (N/A) |
24.94 (23.90) |
-4.17% | Details | |
| 8/18/2026 | Alnylam Pharmaceuticals | ALNY | New Coverage | Outperform (N/A) |
224.60 (236.22) |
5.17% | Details | |
| 8/18/2026 | Ascendis Pharma | ASND | New Coverage | Outperform (N/A) |
247.40 (253.29) |
2.38% | Details | |
| 8/18/2026 | Perspective Therapeutics Inc | CATX | New Coverage | Outperform (N/A) |
3.22 (3.30) |
2.48% | Details | |
| 8/18/2026 | Prime Medicine | PRME | New Coverage | Outperform (N/A) |
3.17 (3.39) |
6.94% | Details | |
| 8/18/2026 | Ionis Pharmaceuticals | IONS | New Coverage | Market Perform (N/A) |
58.63 (59.74) |
1.89% | Details | |
| 8/18/2026 | BioMarin Pharmaceutical Inc. | BMRN | New Coverage | Outperform (N/A) |
66.64 (66.70) |
0.09% | Details | |
| 8/18/2026 | Exelixis | EXEL | New Coverage | Market Perform (N/A) |
52.32 (54.08) |
3.36% | Details |
